Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Acute Myeloid Leukaemia

Autologous stem cell transplantation using modified TAM or combination of triple-alkylating agents conditioning regimens as one of the post-remission treatments in patients with adult acute myeloid leukemia in first complete remission

Bone Marrow Transplantation volume 34, pages 215–220 (2004)Cite this article

Summary:

A total of 174 newly diagnosed adult acute myeloid leukaemia (AML) patients were treated in first complete remission (CR1) using modified TAM or a combination of triple-alkylating agents followed by autologous transplantation (AT). Cytogenetic risk groups were classified and most patients received mobilized peripheral blood stem/progenitor cells (PBSCs). The infused cell dose consisted of a median of 4.1±2 (range, 1.2–17.1)× 106/kg CD34+ cells. With a median follow-up of 51 months (range, 5–131 months) after CR1, the estimated 5-year disease-free survival (DFS) rate was 68 (95% confidence interval (CI), 63–73%) and the event-free survival rate at 5 years was 59 (95% CI, 54–64%). AML patients other than M3 subtype, the long-term DFS rate was 76, 33% for favourable and unfavourable risk groups, respectively. In all, 40 patients had relapses (40/174, 23%) at the median 15 months after CR1 (range, 8–66 months). Overall, seven patients (4%) died in connection with AT. The infused CD34+ cell dose (P=0.0389) was associated with survival by multivariate analysis. In conclusion, two novel conditioning regimens in AT are feasible for adults with variable risk AML followed for over a 10-year period.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. Zittoun RA, Mandelli F, Willemze R et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 1995; 332: 217–223.

    Article  CAS  PubMed  Google Scholar 

  2. Sierra J, Brunet S, Granena A et al. Feasibility and results of bone marrow transplantation after remission induction and intensification chemotherapy in de novo acute myeloid leukemia. Canadian Group for Bone Marrow Transplantation. J Clin Oncol 1996; 14: 1353–1363.

    Article  CAS  PubMed  Google Scholar 

  3. Stein AS, O'Donnell MR, Chai A et al. In vivo purging with high-dose cytarabine followed by high-dose chemoradiotherapy and reinfusion of unpurged bone marrow for adult acute myelogenous leukemia in first complete remission. J Clin Oncol 1996; 14: 2206–2216.

    Article  CAS  PubMed  Google Scholar 

  4. Cassileth PA, Harrington DP, Appelbaum F et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 1998; 339: 1649–1656.

    CAS  PubMed  Google Scholar 

  5. Tsimberidou AM, Stavroyianni N, Viniou N et al. Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia. Cancer 2003; 97: 1721–1731.

    Article  CAS  PubMed  Google Scholar 

  6. Cahn JY, Souillet BG, Pico JL et al. The TAM regimen prior to allogeneic and autologous bone marrow transplantation for high-risk acute lymphoblastic leukemias: a cooperative study of 62 patients. Bone Marrow Transplant 1991; 7: 1–4.

    CAS  PubMed  Google Scholar 

  7. Holmberg LA, Lemirer T, Rowley S et al. High-dose busulfan, melphalan and thiotepa followed by autologous peripheral blood stem cell (PBSC) rescue in patients with advanced stage III/IV ovarian cancer. Bone Marrow Transplant 1998; 22: 651–659.

    Article  CAS  PubMed  Google Scholar 

  8. Mitelman F ( ed.). ISCN 1995: An International System for Human Cytogenetic Nomenclature. Basel, Switzerland: S Karger, 1995.

  9. Slovak ML, Kopecky KJ, Cassileth R et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood 2000; 96: 4075–4083.

    CAS  PubMed  Google Scholar 

  10. Park HS, Kim DW, Kim CC et al. Induction chemotherapy with Idarubicin plus N4-behenoyl-1-β-D-arabinofuranosylcytosine in acute myelogenous leukemia: a newly designed induction regimen – a prospective, cooperative multicenter study. Seminar Hematol 1996; 33 (Suppl. 3): 24–29.

    CAS  Google Scholar 

  11. Miller AB, Hoogstraten B, Staquet M, Winkler A . Reporting results of cancer treatment. Cancer 1981; 47: 207–214.

    Article  CAS  PubMed  Google Scholar 

  12. Amadori S, Testi AM, Arico M et al. Prospective comparative study of bone marrow transplantation and postremission chemotherapy for childhood acute myelogenous leukemia. J Clin Oncol 1993; 11: 1046–1054.

    Article  CAS  PubMed  Google Scholar 

  13. Ewing JC, Robertson JD, Kell WJ et al. Autologous peripheral blood stem cell transplantation in first remission adult acute myeloid leukaemia – an intention to treat analysis and comparison of outcome using a predictive model based on the MRC AML10 cohort. Hematology 2003; 8: 83–90.

    Article  CAS  PubMed  Google Scholar 

  14. Collisson EA, Lashkari A, Malone R et al. Long-term outcome of autologous transplantation of peripheral blood progenitor cells as postremission management of adult acute myelogenous leukemia in first complete remission. Leukemia 2003; 17: 2183–2188.

    Article  CAS  PubMed  Google Scholar 

  15. Weaver CH, Bensinger WI, Appelbaum F et al. Phase I study of high-dose busulfan, melphalan, thiotepa with autologous stem cell support in patients with refractory malignancies. Bone Marrow Transplant 1994; 14: 813–819.

    CAS  PubMed  Google Scholar 

  16. Schiffman KS, Bensinger WI, Appelbaum FR et al. Phase II study of high-dose busulfan, melphalan and thiotepa with autologous peripheral blood stem cell support in patients with malignant disease. Bone Marrow Transplant 1996; 17: 943–950.

    CAS  PubMed  Google Scholar 

  17. Holmberg LA, Demirer T, Rowley S et al. High-dose busulfan, melphalan and thiotepa followed by autologous peripheral blood stem cell (PBSC) rescue in patients with advanced stage III/IV ovarian cancer. Bone Marrow Transplant 1998; 22: 651–659.

    Article  CAS  PubMed  Google Scholar 

  18. Keating S, Suciu S, de Witte T et al. The stem cell mobilization capacity of patients with acute myeloid leukemia in complete remission correlates with relapse risk: results of the EORTC-GIMEMA AML-10 trial. Leukemia 2003; 17: 60–67.

    Article  CAS  PubMed  Google Scholar 

  19. Feller N, Schuurhuis GJ, van der Pol MA et al. High percentage of CD34-positive cells in autologous AML peripheral blood stem cell products reflects inadequate in vivo purging and low chemotherapeutic toxicity in a subgroup of patients with poor clinical outcome. Leukemia 2003; 17: 68–75.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology, Department of Internal Medicine, Catholic Hemopoietic Stem Cell Transplantation Center, The Catholic University of Korea College of Medicine, Seoul, Korea

    H-J Kim, W-S Min, K-S Eom, S-J Park, Y-H Park, D-W Kim, J-W Lee, C-W Park & C-C Kim

Authors
  1. H-J Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W-S Min
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K-S Eom
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S-J Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Y-H Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D-W Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J-W Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. C-W Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. C-C Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to W-S Min.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kim, HJ., Min, WS., Eom, KS. et al. Autologous stem cell transplantation using modified TAM or combination of triple-alkylating agents conditioning regimens as one of the post-remission treatments in patients with adult acute myeloid leukemia in first complete remission. Bone Marrow Transplant 34, 215–220 (2004). https://doi.org/10.1038/sj.bmt.1704556

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704556

Keywords

This article is cited by

Search

Advanced search

Quick links